Elite Pharmaceuticals, Inc.
ELTP
$0.40
$0.000.73%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -13.03% | -9.67% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -13.03% | -9.67% | |||
| Cost of Revenue | -16.24% | 71.34% | |||
| Gross Profit | -7.96% | -48.31% | |||
| SG&A Expenses | -38.43% | 18.02% | |||
| Depreciation & Amortization | -1.72% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -19.68% | 51.84% | |||
| Operating Income | 9.73% | -62.15% | |||
| Income Before Tax | 32.78% | 2,880.98% | |||
| Income Tax Expenses | 12.68% | -62.64% | |||
| Earnings from Continuing Operations | 35.70% | 332.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 35.70% | 332.85% | |||
| EBIT | 9.73% | -62.15% | |||
| EBITDA | 9.21% | -61.04% | |||
| EPS Basic | 35.16% | 332.73% | |||
| Normalized Basic EPS | 32.97% | 3,133.33% | |||
| EPS Diluted | 9.26% | 154.00% | |||
| Normalized Diluted EPS | 32.56% | 2,966.67% | |||
| Average Basic Shares Outstanding | 0.21% | 0.33% | |||
| Average Diluted Shares Outstanding | -0.06% | 6.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||